



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

October 28, 2005

FILE COPY

Mr. Charles J. Raubicheck
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, New York 10151

Dear Mr. Raubicheck:

Your petition, on behalf of Pharmacaps Inc. of High Point, North Carolina, requesting the Food and Drug Administration to refuse to approve the Section 505(b)(2) New Drug Application ("NDA") No. 21-863 filed by Ranbaxy Laboratories Ltd., was received by this office on 10/28/2005. It was assigned docket number 200P-0436/CP 1 and it was filed on 10/28/2005. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Division of Dockets Management
Office of Management Programs
Office of Management

2005P-0436

ACK 1